PB2289: PRELIMINARY DATA FROM A FIRST-IN HUMAN PHASE II STUDY OF SEQUENTIAL USE OF SELINEXOR AND CD19 CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELL THERAPY (CART19) IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

Detalles Bibliográficos
Autores principales: Zhang, Ying, Zong, Xiangping, LI, Jiaqi, Jia, Sixun, Geng, Hongzhi, Zeng, Liangyu, Yang, Qin, Cai, Wenzhi, Liu, Shuangzhu, Lu, Yutong, Yu, Lei, LI, Caixia, Wu, Depei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429579/
http://dx.doi.org/10.1097/01.HS9.0000975884.42135.d7
_version_ 1785090750135926784
author Zhang, Ying
Zong, Xiangping
LI, Jiaqi
Jia, Sixun
Geng, Hongzhi
Zeng, Liangyu
Yang, Qin
Cai, Wenzhi
Liu, Shuangzhu
Lu, Yutong
Yu, Lei
LI, Caixia
Wu, Depei
author_facet Zhang, Ying
Zong, Xiangping
LI, Jiaqi
Jia, Sixun
Geng, Hongzhi
Zeng, Liangyu
Yang, Qin
Cai, Wenzhi
Liu, Shuangzhu
Lu, Yutong
Yu, Lei
LI, Caixia
Wu, Depei
author_sort Zhang, Ying
collection PubMed
description
format Online
Article
Text
id pubmed-10429579
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104295792023-08-17 PB2289: PRELIMINARY DATA FROM A FIRST-IN HUMAN PHASE II STUDY OF SEQUENTIAL USE OF SELINEXOR AND CD19 CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELL THERAPY (CART19) IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA Zhang, Ying Zong, Xiangping LI, Jiaqi Jia, Sixun Geng, Hongzhi Zeng, Liangyu Yang, Qin Cai, Wenzhi Liu, Shuangzhu Lu, Yutong Yu, Lei LI, Caixia Wu, Depei Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429579/ http://dx.doi.org/10.1097/01.HS9.0000975884.42135.d7 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Publication Only
Zhang, Ying
Zong, Xiangping
LI, Jiaqi
Jia, Sixun
Geng, Hongzhi
Zeng, Liangyu
Yang, Qin
Cai, Wenzhi
Liu, Shuangzhu
Lu, Yutong
Yu, Lei
LI, Caixia
Wu, Depei
PB2289: PRELIMINARY DATA FROM A FIRST-IN HUMAN PHASE II STUDY OF SEQUENTIAL USE OF SELINEXOR AND CD19 CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELL THERAPY (CART19) IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
title PB2289: PRELIMINARY DATA FROM A FIRST-IN HUMAN PHASE II STUDY OF SEQUENTIAL USE OF SELINEXOR AND CD19 CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELL THERAPY (CART19) IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
title_full PB2289: PRELIMINARY DATA FROM A FIRST-IN HUMAN PHASE II STUDY OF SEQUENTIAL USE OF SELINEXOR AND CD19 CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELL THERAPY (CART19) IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
title_fullStr PB2289: PRELIMINARY DATA FROM A FIRST-IN HUMAN PHASE II STUDY OF SEQUENTIAL USE OF SELINEXOR AND CD19 CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELL THERAPY (CART19) IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
title_full_unstemmed PB2289: PRELIMINARY DATA FROM A FIRST-IN HUMAN PHASE II STUDY OF SEQUENTIAL USE OF SELINEXOR AND CD19 CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELL THERAPY (CART19) IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
title_short PB2289: PRELIMINARY DATA FROM A FIRST-IN HUMAN PHASE II STUDY OF SEQUENTIAL USE OF SELINEXOR AND CD19 CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELL THERAPY (CART19) IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
title_sort pb2289: preliminary data from a first-in human phase ii study of sequential use of selinexor and cd19 chimeric antigen receptor modified t-cell therapy (cart19) in patients with relapsed or refractory b-cell non-hodgkin lymphoma
topic Publication Only
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429579/
http://dx.doi.org/10.1097/01.HS9.0000975884.42135.d7
work_keys_str_mv AT zhangying pb2289preliminarydatafromafirstinhumanphaseiistudyofsequentialuseofselinexorandcd19chimericantigenreceptormodifiedtcelltherapycart19inpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma
AT zongxiangping pb2289preliminarydatafromafirstinhumanphaseiistudyofsequentialuseofselinexorandcd19chimericantigenreceptormodifiedtcelltherapycart19inpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma
AT lijiaqi pb2289preliminarydatafromafirstinhumanphaseiistudyofsequentialuseofselinexorandcd19chimericantigenreceptormodifiedtcelltherapycart19inpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma
AT jiasixun pb2289preliminarydatafromafirstinhumanphaseiistudyofsequentialuseofselinexorandcd19chimericantigenreceptormodifiedtcelltherapycart19inpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma
AT genghongzhi pb2289preliminarydatafromafirstinhumanphaseiistudyofsequentialuseofselinexorandcd19chimericantigenreceptormodifiedtcelltherapycart19inpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma
AT zengliangyu pb2289preliminarydatafromafirstinhumanphaseiistudyofsequentialuseofselinexorandcd19chimericantigenreceptormodifiedtcelltherapycart19inpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma
AT yangqin pb2289preliminarydatafromafirstinhumanphaseiistudyofsequentialuseofselinexorandcd19chimericantigenreceptormodifiedtcelltherapycart19inpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma
AT caiwenzhi pb2289preliminarydatafromafirstinhumanphaseiistudyofsequentialuseofselinexorandcd19chimericantigenreceptormodifiedtcelltherapycart19inpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma
AT liushuangzhu pb2289preliminarydatafromafirstinhumanphaseiistudyofsequentialuseofselinexorandcd19chimericantigenreceptormodifiedtcelltherapycart19inpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma
AT luyutong pb2289preliminarydatafromafirstinhumanphaseiistudyofsequentialuseofselinexorandcd19chimericantigenreceptormodifiedtcelltherapycart19inpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma
AT yulei pb2289preliminarydatafromafirstinhumanphaseiistudyofsequentialuseofselinexorandcd19chimericantigenreceptormodifiedtcelltherapycart19inpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma
AT licaixia pb2289preliminarydatafromafirstinhumanphaseiistudyofsequentialuseofselinexorandcd19chimericantigenreceptormodifiedtcelltherapycart19inpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma
AT wudepei pb2289preliminarydatafromafirstinhumanphaseiistudyofsequentialuseofselinexorandcd19chimericantigenreceptormodifiedtcelltherapycart19inpatientswithrelapsedorrefractorybcellnonhodgkinlymphoma

Ejemplares similares